Table 1.
Study population demographic and clinical data at baseline.
| Clinical characteristics | De novo PD |
|---|---|
| No. of individuals (N) | 376 |
| Age (mean years, SD) | 62.2 (9.8) |
| No. of males (N, %) | 240 (63.8) |
| Disease duration (mean years, SD) | 2.0 (2.0) |
| Total UPDRS (mean, SD) | 32.2 (13.1) |
| (median, range) | 31 (7, 70) |
| UPDRS-III (mean, SD) | 20.9 (8.9)”” |
| (median, range) | 20 (4, 51) |
| PIGD score (mean, SD) | 1.1 (1.1) |
| (median, range) | 1 (0, 6) |
| Tremor score (mean, SD) | 5.4 (3.5) |
| (median, range) | 5 (0, 20) |
| Akinetic-rigid score (mean, SD) | 13.6 (7.3) |
| (median, range) | 12 (2, 34) |
| MoCA (mean, SD) | 27.1 (2.4) |
| (median, range) | 27 (17, 30) |
| Serum NFL levels (mean pg/ml, SD) | 13.0 (7.1) |
| (median, range) | 11.5 (1.8, 76.6) |
| DAT binding ratio (mean, SD) | 0.8 (0.3) |
| (median, range)a | 0.8 (0.2, 2.2) |
a
355 participants underwent baseline DaTscan SPECT.